Skip to main content

Thomas Powles, MBBS, MD

Thomas Powles, MBBS, MD
Conference Coverage
01/27/2024
Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.
Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.
Thomas Powles, MBBS, MD,...
01/27/2024
Oncology